Enochian Biosciences, Inc. (ENOB): Price and Financial Metrics
ENOB Price/Volume Stats
| Current price | $0.70 | 52-week high | $2.99 |
| Prev. close | $0.70 | 52-week low | $0.39 |
| Day low | $0.70 | Volume | 88,300 |
| Day high | $0.75 | Avg. volume | 137,347 |
| 50-day MA | $0.64 | Dividend yield | N/A |
| 200-day MA | $1.13 | Market Cap | 40.80M |
ENOB Stock Price Chart Interactive Chart >
Enochian Biosciences, Inc. (ENOB) Company Bio
Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, focuses on development of human therapeutics for infectious diseases and cancers. The company's lead candidate include ENOB-HV-01 for autologous HIV curative treatment. Its pipeline development products consist of ENOB-HV-11, a preventive HIV vaccine; and ENOB-HV-12, a therapeutic HIV vaccine. The company's pipeline development products also include ENOB-HB-01, a coopting Hepatitis B polymerase; ENOB-DC-01, an off-the-shelf DC vaccine pulsed with MCV lysate; ENOB-DC-11 innovative DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intratumoral injection. The company has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Center, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. Enochian Biosciences, Inc. is headquartered in Los Angeles, California.
ENOB Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -91.49% |
| 5-year | -85.57% |
| YTD | N/A |
| 2023 | 0.00% |
| 2022 | -85.87% |
| 2021 | 147.12% |
| 2020 | -41.24% |
| 2019 | -28.29% |
Loading social stream, please wait...